FDA approves expanded use of Pfizer's RSV vaccine for adults under 50

Pfizer Inc. ( $PFE (+2,63 %) ) has received U.S. Food and Drug Administration (FDA) approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, ABRYSVO, to include adults aged 18 through 59 who are at increased risk of lower respiratory tract disease (LRTD) caused by RSV. This decision, announced today, broadens the vaccine's indication, which already covers individuals 60 years and older and pregnant individuals during their third trimester.

RSV poses a significant health risk, particularly to younger adults with chronic conditions such as obesity, diabetes, and heart failure. With this new approval, ABRYSVO becomes the sole RSV vaccine indicated for adults under 50 at increased risk, complementing its existing authorizations.

ABRYSVO is a bivalent vaccine, designed to protect against both major subgroups of RSV, without the need for adjuvants.

SRC : Pfizer Press Statement